So much going on behind the scenes regards to patents ...
Who gains control of the PS Targeting patents, because there are hundreds of blood tests on hundreds of conditions and since flipped PS detections are not standing still, it can be captured via meeical device implants, forwarded to ones Apple watch and further forwarded to MDs that can analyze those PS Targeting Biomarkers
UTSWM must like the idea of receiving back exosome research from Peregrine that collaborated on such data and those collaborations mean much more after judge rules just this week that any such collaboration could spark some fireworks around the BOD table at Avid Bioservices which may be proven to have immediate fiduciary duties to protect PS Targeting patents, especially if Oncologie paid for delay